MTOR and neoplasm: Of the seven drugs, a multitude of their targeted pathways were associated with tumor cell prolifiation, such as, cell cycle, chromatin histone acetylation, PI3K/MTOR signaling, mitosis, and kinases, which were the latent targets of patients in the high-risk group (Figure 4D).